

Part 5

Science Industry Endowment Fund

- 166 Trustee's report
- 169 Independent Auditor's report for SIEF
- 171 SIEF financial statements

Trustee's report

I'm delighted to have recently become Trustee of the Science and Industry Endowment Fund (SIEF) and see first-hand the extraordinary research in which it invests. I'm especially glad to see the rejuvenation of the Fund through a Gift from CSIRO, enabled by the fast Wireless Local Area Network (WLAN) patent litigation in 2009. I am excited by the science the Fund is supporting and the national benefit it is delivering.

I am in the rare position of being Trustee of the SIEF and a past recipient of SIEF funding, having been involved in the Stem Cells Biology Research Project from 2011 to 2016 when I was at the Walter and Eliza Hall Institute of Medical Research. In collaboration with CSIRO and CSL, we worked together on 2 projects to develop more effective strategies for creating blood platelets in a clinical setting to support medical treatments. The projects combined cutting-edge research with well-established routes to clinical and commercial translation, but were only possible because of the unique role SIEF plays in our research ecosystem.

Over the last year, SIEF has funded programs for research into areas as diverse as renewable energy, research infrastructure, and scholarships that create and sustain young researchers. This is research that assists Australian industry, furthers the interests of the Australian community, or contributes to the achievement of Australia's national objectives. Collaboration across organisations is also vital to the success of SIEF-funded projects. I am pleased to share some of this year's highlights from the Fund.

Research infrastructure

Facilities and equipment are critical for research institutions to deliver national benefit and SIEF has been funding this critical component of the innovation system through its Medium Equipment Program (MEP) since 2017. MEP has funded \$33 million for equipment and refurbishment of facilities to the value of up to \$4 million per asset.

This year, SIEF has allocated \$6.5 million towards building the nation's capability in biomedical manufacturing, and agriculture and food.

The National Vaccine and Therapeutics Laboratory will comprise multiple facilities enabling the process development, manufacture and quality control of investigational materials for evaluation in human and veterinary preclinical and clinical studies. The facility will address an unmet need in the Australian medical research industry of a nationally available capability for development of biological formulations that are stable for vaccine antigens and biologicals in their final product presentation.

Aquaculture, agriculture and the environment will benefit from a next-generation infrared mass spectrophotometer for the analysis of carbon, nitrogen, and sulphur isotopes in bulky samples with low signal-to-noise ratios. The new instrument will strengthen CSIRO's capability to analyse organic materials and will be central to existing national collaborative projects.

The impact of SIEF's focus on research infrastructure has been demonstrated by investment in the FloWorks laboratory, through the MEP, in 2017. This investment de-risked the development of Australian-manufactured products by providing a scale-up platform accessible by SMEs and larger chemical manufacturers. FloWorks also enabled the chemical industry to adopt more efficient and cost-effective processing methods important to making Australia's chemical industry globally competitive. SIEF has commissioned an independent analysis on the impact of the FloWorks' laboratory, the results of which can be found on page 168 of this Annual Report.

Collaboration

Australian research can have deep and significant impact when researchers and institutions collaborate with each other and their international peers. Since 2009, SIEF has championed collaboration across its portfolio of programs. The SIEF National Collaborative Missions Program established in 2023 continues this focus providing funding for Australian and international research institutions to jointly address the challenges posed by a changing climate and work towards achieving net-zero emissions. This includes supporting the Electric Power Innovation for a Carbon-free Society (EPICS) and the global Hydrogen Production Technologies (HyPT) Centres as part of the US National Science Foundation Global Centers in Climate Change and Clean Energy. The EPICS Centre aims to guarantee stable and secure system operation amidst high penetration of variable energy sources. The HyPT Centre will advance technology commercialisation for hydrogen production.

Participating Australian organisations include CSIRO, University of Melbourne, Monash University, University of Adelaide, Flinders University and Curtin University.

Renewable energy technologies

SIEF is supporting the development of novel low and zero emissions technologies that will contribute to Australia's transition to net zero. Through the Experimental Development Program (EDP), SIEF has funded a project to advance perovskite solar cell technology and build a prototype to generate hydrogen from steam as a byproduct of steel making. A recently approved EDP project will develop a prototype adapted diesel engine at commercial scale (named BioDICE), using fuel produced from biomass. Using a low-temperature carbonisation process to convert the biomass to fuel, 40 per cent thermal efficiency can be achieved, which is double that of traditional steam or gasification-based cycles of similar capacity.

Using readily available biomass sources such as invasive woody weeds, it is envisaged that the technology could potentially generate 50 per cent of Australia's current electricity demand as dispatchable power, which will contribute to Australia's commitment to a reduction in greenhouse gas emissions and provide opportunities for regional development.

Supporting students

The NSW Generation STEM Program continues to develop a pipeline for STEM-ready school and university graduates through its 3 programs. The Community Partnerships Program has extended its presence in regional NSW to include Albury, Dubbo and the Queanbeyan-Yass area. Eighty-five schools participated in the program in the 2023 calendar year. Deadly in Generation STEM continues to engage students in the Moree and Illawarra-Shoalhaven regions. Eighty-eight students participated in the program and a STEM-experience on-Country camp was offered for Illawarra Aboriginal students, providing education about science, their own Indigenous identities and careers for their future. Generation STEM Links experienced a significant increase in participation by industries, providing university students more opportunities to gain hands-on experience in a STEM industry. Regional businesses have shown strong interest with almost 60 per cent of new placement requests coming from outside of Sydney, which has led to a greater diversity of STEM sectors participating in the program. The program has helped regional businesses find and retain local students, which also contributes to regional development.

My role as Trustee is greatly assisted by the Fund's Advisory Councils and other experts who have generously supported the Fund by providing guidance and insight on a *pro bono* basis. Their contributions have ensured investments are directed to where the greatest difference can be made.



Dr Doug Hilton AO
Trustee, SIEF

FloWorks

Background

FloWorks, a state-of-the-art technology transfer facility, has been advancing flow chemistry technologies since its launch in October 2019. Supported by diverse funding streams from both government and industry, including the SIEF Medium Equipment Program (MEP), FloWorks has developed specialised technologies in continuous flow chemistry such as controlled polymerisation and catalysis. The facility offers services such as designing flow chemistry processes, installing and commissioning systems, training, and equipment testing (research.csiro.au/floworks).

Industry challenge

Traditional batch methods in chemical and pharmaceutical production face limitations like low efficiency, lack of scalability, high costs, and inconsistent product quality. The absence of dedicated infrastructure has been a major barrier, leading to logistical challenges, low efficiency, and productivity issues, thus hindering Australia's growth in flow chemistry research and development.

CSIRO's response

To address these challenges, CSIRO established FloWorks, a state-of-the-art centre for industrial flow chemistry research, with a \$4.5 million investment, supported significantly by SIEF with additional funds for equipment. Launched in October 2019 in Clayton, Victoria, this 400 m² facility centralises infrastructure, enhancing efficiency and accessibility for researchers. FloWorks aims to revolutionise chemical manufacturing with cleaner, more sustainable, and efficient processes and advance automation through smart monitoring and online analysis.



Prospective impacts

FloWorks has significantly enhanced Australia's flow chemistry capabilities, driving research and innovation, commercial success, environmental sustainability, and social wellbeing, creating benefit for the nation. The facility's advanced infrastructure has enabled high-quality research and international collaborations with partners like the University of Melbourne, Research Institute Juelich, Germany and Imperial College London. Commercially, FloWorks has facilitated the development of new products and markets through partnerships with industry leaders such as Boron Molecular and Precision Catalysts, leading to innovations like the MS3 varnish and commercial RAFT agents, thus boosting economic growth. Environmentally, projects like the Movable Hydrogen Generator, in collaboration with Advanced Carbon Engineering, have potential to support critical national agenda to achieve net zero emissions by 2050. Socially, FloWorks has advanced public health and safety through safer manufacturing processes and provided extensive training, enhancing the workforce's technical skills and supporting energy security with innovative hydrogen solutions.

SIEF's role

SIEF's MEP grant has been instrumental in advancing the FloWorks initiative by providing essential financial support for the purchase of critical equipment that enabled the development and success of high-impact projects. This support has enhanced R&D capabilities in areas such as Catalytic Static Mixer (CSM) technology, Metal-Organic Frameworks (MOFs), and Flow Chemistry Polymerisation. Additionally, the SIEF-MEP facilitated strategic planning and resource management within FloWorks, helping to outline an ideal future equipment portfolio and attract further funding. Overall, SIEF has been a crucial enabler for both large-scale and smaller projects, significantly impacting FloWorks' strategic research capabilities and its ability to capitalise on emerging opportunities.

The FloWorks facility operates a unique suite of hydrogen reactors and large walk-in rooms for pilot and demonstrator scale testing.



INDEPENDENT AUDITOR'S REPORT

To the Minister for Industry and Science

Opinion

In my opinion, the financial statements of the Science and Industry Endowment Fund (the Entity) for the year ended 30 June 2024 present fairly, in all material respects, the financial position of the Entity as at 30 June 2024 and its financial performance and cash flows for the year then ended in accordance with Australian Accounting Standards – Simplified Disclosures.

The financial statements of the Entity, which I have audited, comprise the following as at 30 June 2024 and for the year then ended:

- Statement by the Trustee and Chief Financial Officer;
- Statement of Comprehensive Income;
- Statement of Financial Position;
- Statement of Changes in Equity;
- Cash Flow Statement; and
- Notes to and forming part of the financial statements, comprising material accounting policy information and other explanatory information.

Basis for opinion

I conducted my audit in accordance with the Australian National Audit Office Auditing Standards, which incorporate the Australian Auditing Standards. My responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of my report. I am independent of the Entity in accordance with the relevant ethical requirements for financial statement audits conducted by the Auditor-General and their delegates. These include the relevant independence requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) to the extent that they are not in conflict with the *Auditor-General Act 1997*. I have also fulfilled my other responsibilities in accordance with the Code. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

Trustee's responsibility for the financial statements

The Chief Executive of the Commonwealth Scientific and Industrial Research Organisation (the Trustee) is responsible for the preparation and fair presentation of financial statements that comply with Australian Accounting Standards – Simplified Disclosures. The Trustee is also responsible for such internal control as they determine is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustee is responsible for assessing the ability of the Entity to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustee either intend to liquidate the Entity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

My objective is to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian National Audit Office Auditing Standards will always detect a material misstatement when it

GPO Box 707, Canberra AC 2601
38 Sydney Avenue, Forrest ACT 2603
Phone (02) 6203 7300

exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with the Australian National Audit Office Auditing Standards, I exercise professional judgement and maintain professional scepticism throughout the audit. I also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control;
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustee;
- conclude on the appropriateness of the Trustee's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern; and
- evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

I communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

Australian National Audit Office



Jeffrey Hobson

Executive Director

Delegate of the Auditor-General

Canberra

21 August 2024

SCIENCE AND INDUSTRY ENDOWMENT FUND

Statement by the Trustee and Chief Financial Officer

for the period ended 30 June 2024

STATEMENT BY THE TRUSTEE AND CHIEF FINANCIAL OFFICER OF COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (CSIRO) AS SERVICE PROVIDER TO THE SCIENCE AND INDUSTRY ENDOWMENT FUND

The attached financial report for the year ended 30 June 2024 has been prepared based on properly maintained financial records and in accordance with Australian Accounting Standards simplified disclosure requirements and the requirements of the *Science and Industry Endowment Act 1926*, and present fairly the financial position of the Science and Industry Endowment Fund as at 30 June 2024 and its performance and cashflows for the year then ended.

In our opinion, at the date of this statement, there are reasonable grounds to believe that the Science and Industry Endowment Fund will be able to pay its debts as and when they become due and payable.


Signed in accordance with a resolution of the Trustee.



Dr Doug Hilton AO

Trustee of the Science and Industry Endowment Fund

20 August 2024



Stewart Walters

Chief Financial Officer of CSIRO as service provider to the Science and Industry Endowment fund

20 August 2024

SCIENCE AND INDUSTRY ENDOWMENT FUND**Statement of Comprehensive Income***for the period ended 30 June 2024*

	Notes	2024	2023
Expenses			
Scientific research grants	1.1A	12,352,674	11,057,587
Service fee under services agreement with CSIRO	1.1B	531,000	516,130
Audit fees	1.1C	19,000	18,870
Other fees	1.1D	1	10,071
Total expenses		12,902,675	11,602,658
Revenue			
Interest revenue	1.2A	5,814,909	3,153,988
Gifts	1.2B	8,000,000	39,000,000
Total revenue		13,814,909	42,153,988
Net (loss)/surplus for the period		912,234	30,551,330
Other comprehensive income		-	-
Total comprehensive income		912,234	30,551,330

The above statement should be read in conjunction with the accompanying notes.

SCIENCE AND INDUSTRY ENDOWMENT FUND**Statement of Financial Position***as at 30 June 2024*

	Notes	2024	2023
ASSETS			
Current			
Cash and cash equivalents	2.1A	119,500,327	118,457,950
Trade and other receivables	2.1B	1,744,969	1,875,112
Total assets		121,245,296	120,333,062
LIABILITIES			
Current			
Suppliers payable		-	-
Total Liabilities		-	-
Net assets		121,245,296	120,333,062
EQUITY			
Contributed equity		200,000	200,000
Retained earnings		121,045,296	120,133,062
Total equity		121,245,296	120,333,062

The above statement should be read in conjunction with the accompanying notes.

SCIENCE AND INDUSTRY ENDOWMENT FUND**Statement of Changes in Equity***for the period ended 30 June 2024*

	Retained Earnings	Contributed Equity	Total Equity
Opening balance 1 July 2023	120,133,062	200,000	120,333,062
Net surplus	912,234	-	912,234
Closing balance 30 June 2024	121,045,296	200,000	121,245,296

	Retained Earnings	Contributed Equity	Total Equity
Opening balance 1 July 2022	89,581,732	200,000	89,781,732
Net surplus	30,551,330	-	30,551,330
Closing balance 30 June 2023	120,133,062	200,000	120,333,062

The above statement should be read in conjunction with the accompanying notes.

SCIENCE AND INDUSTRY ENDOWMENT FUND**Cash Flow Statement***for the period ended 30 June 2024*

	Notes	2024	2023
Operating activities			
Cash received			
CSIRO gift		8,000,000	39,000,000
Interest received		5,483,477	2,104,819
GST credits received		1,751,842	742,938
Total cash received		15,235,319	41,847,757
Cash used			
Payments to grantees		13,587,941	12,163,346
Other payments		605,001	599,571
Total cash used		14,192,942	12,762,917
Net cash flows from operating activities		1,042,377	29,084,840
Net increase in cash held		1,042,377	29,084,840
Cash and cash equivalents at the beginning of the reporting period		118,457,950	89,373,110
Cash and cash equivalents at the end of the reporting period		119,500,327	118,457,950

The above statement should be read in conjunction with the accompanying notes.

SCIENCE AND INDUSTRY ENDOWMENT FUND

NOTES TO AND FORMING PART OF THE FINANCIAL REPORT

for the period ended 30 June 2024

Overview

The Science and Industry Endowment Fund (referred to as the Fund) was established under the *Science and Industry Endowment Act 1926* with the Trustee of the Fund being the Commonwealth Scientific and Industrial Research Organisation's (CSIRO) Chief Executive and is a not-for-profit entity. An appropriation of 100,000 pounds was received at the time the Fund was established. The principal activity of the Fund is to provide assistance to persons engaged in scientific research and in the training of students in scientific research. Dr Doug Hilton AO was appointed CSIRO Chief Executive (and SIEF Trustee) from 29 September 2023. For the period 1 July 2023 to 29 September 2023, Kirsten Rose was the acting CSIRO Chief Executive (and SIEF Trustee).

In October 2009 the Minister for Innovation, Industry, Science and Research announced a gift of \$150 million to be donated by CSIRO to the Fund. The gift is intended to be used for scientific research for the purposes of assisting Australian industry and furthering the interests of the Australian community or contributing to the achievement of Australian national objectives. The gift was made subject to the terms of a Deed of Gift between the Trustee and CSIRO dated 15 October 2009. Between financial years 2017/18 and 2022/23 CSIRO made further gifts totalling \$90 million to the Fund, with an additional \$8 million in financial year 2023/24. These gifts were also made subject to the terms of the Deed of Gift between the Trustee and CSIRO dated 15 October 2009.

In June 2017, the NSW Government acting through the NSW Department of Industry provided a \$25 million endowment to the Fund to create the NSW Generation STEM Program. The program will be delivered over a 10-year period and will implement activities including research, to increase the supply of Science, Technology, Engineering and Mathematics (STEM) skilled labour to meet the current and future needs of New South Wales. The total cash payments made by the Fund in financial year 2023/24 under the NSW Endowment were \$1,530,000 (GST exclusive).

In November and December 2018, National ICT Australia Limited (NICTA), a controlled entity of CSIRO, provided two gifts to the Fund in the total amount of \$20 million to fund the Future National ICT Industry Platform Program. A further \$5 million was provided to the Fund by NICTA in December 2019. The program is to support research activities and projects at a scale that address challenges in the field of Information and Communications Technology (ICT) and it is intended that the outcomes from the Program will benefit Australia by helping create new Australian technology-based industries and/or applied technology platforms that can reach a global scale. The total payments made by the Fund in financial year 2023/24 under the Future National ICT Industry Platform Program were \$125,000 (GST exclusive).

In one financial year a maximum amount of \$25 million exclusive of Goods and Services Tax (GST) can be disbursed from the Fund for the CSIRO GIFT Programs, NSW Generation STEM Program and the Future National ICT Industry Platform Program (under the Deeds of Gift/Endowment). The total payments made by the Fund under these gifts and programs in financial year 2023/24 were \$12,884,673 (GST exclusive). This includes Scientific research grant payments, service, audit and other fees.

Basis of Preparation of the Financial Statements

The financial statements for the Fund are general purpose financial statements and are required by Section 10 of the *Science and Industry Endowment Act 1926*. The financial statements have been prepared in accordance with the Australian Accounting Standards and Interpretations, including *AASB 1060 General Purpose Financial Statements – Simplified Disclosures for For-Profit and Not-for Profit Entities* issued by the Australian Accounting Standards Board (AASB) that apply for the reporting period.

The financial statements have been prepared on an accrual basis and are in accordance with the historical cost convention. No allowance is made for the effect of changing prices on the results or the financial position. The financial statements are presented in Australian dollars and values are rounded to the nearest dollar unless otherwise specified.

SCIENCE AND INDUSTRY ENDOWMENT FUND

NOTES TO AND FORMING PART OF THE FINANCIAL REPORT

for the period ended 30 June 2024

Key Judgements and Estimates

The accounting policies are set out below. Within the current financial year, there were no significant judgements or estimates used in the preparation of the financial statements.

Adoption of new and future Australian Accounting Standards

All new, revised and amending standards and/or interpretations that were issued prior to the signing of these statements and applicable to the current reporting period were adopted by the Fund and did not have a material effect on the financial statements. The Fund has not early adopted any standards, interpretations or amendments that have been issued and are not yet effective.

Taxation

The Fund is exempt from all forms of taxation except Goods and Services Tax ('GST').

Events after the Reporting Period

At the time of signing of the financial statements, the Trustee is not aware of any other significant events occurring after the reporting date that could impact on the financial report.

SCIENCE AND INDUSTRY ENDOWMENT FUND

NOTES TO AND FORMING PART OF THE FINANCIAL REPORT

for the period ended 30 June 2024

1.1 Expenses	2024	2023
<u>1.1A: Scientific research grants</u>		
Research Infrastructure Program	9,458,000	5,622,000
Promotion of Science Program - Scholarships and Fellowships	100,000	100,000
Experimental Development Program	1,376,674	1,960,587
NSW Endowment Grant	1,400,000	3,375,000
Education and Outreach Program	18,000	-
Total scientific research grants	12,352,674	11,057,587

Accounting Policy
 The Fund awards grants to support approved eligible applications and activities in instalments, subject to the completion by Grant Recipients of funding milestones which are verified through provision of satisfactory Progress Reports to the Fund Manager. All costs associated with providing scientific research grants are expensed at acceptance of relevant Progress Reports.

	2024	2023
<u>1.1B: Service fee under services agreement with CSIRO</u>		
Service fee	531,000	516,130
Total service fee	531,000	516,130

Accounting Policy
 Services fees under services agreement with CSIRO are expensed as incurred.

	2024	2023
<u>1.1C: Audit fees</u>		
Audit fees	19,000	18,870
Total audit fees	19,000	18,870

Accounting Policy
 Audit fees are recognised when they have been incurred (irrespective of having been invoiced). Outside of audit services, no other services have been provided by the auditors.

	2024	2023
<u>1.1D: Other fees</u>		
Bank fees	1	71
Professional fees	-	10,000
Total other fees	1	10,071

Accounting Policy
 All other fees include operational expenses and are expensed as incurred.

SCIENCE AND INDUSTRY ENDOWMENT FUND

NOTES TO AND FORMING PART OF THE FINANCIAL REPORT

for the period ended 30 June 2024

1.2 Income and Gains

	2024	2023
1.2A: Interest revenue		
Bank account interest	645,402	266,712
Term deposits interest	5,169,507	2,887,276
Total interest revenue	5,814,909	3,153,988

Accounting Policy

Interest revenue is recognised using the effective interest method as set out in *AASB 9 Financial Instruments*.

	2024	2023
1.2B: Gifts		
CSIRO gift	8,000,000	39,000,000
Total gifts	8,000,000	39,000,000

Accounting Policy

Gifts are recognised as income when the entity gains control of the funds, where the consideration to acquire an asset is significantly less than fair value. Gifts, bequests or donations receivable are recognised at their nominal amounts as a financial asset under *AASB 9 Financial Instruments* as highlighted in paragraph 8 of *AASB 1058 Income of Not-for-Profit Entities*. The additional \$8 million gift received from CSIRO in 2023/24 is to be used to further Fund objectives.

2.1 Assets

	2024	2023
2.1A: Cash and cash equivalents		
Cash at bank	16,700,327	45,867,950
Term deposits	102,800,000	72,590,000
Total Cash and cash equivalents	119,500,327	118,457,950

Accounting Policy

Cash and cash equivalents include cash on hand and demand deposits in bank accounts with an original maturity of 12 months or less that are readily convertible to known amounts of cash and subject to insignificant risk of change in value. Cash is recognised at its nominal amount.

	2024	2023
2.1B: Trade and other receivables		
Interest receivable	1,581,469	1,250,037
GST receivable	163,500	625,075
Total receivables	1,744,969	1,875,112
Less impairment loss allowance	-	-
Total Trade and other receivables	1,744,969	1,875,112

Accounting Policy

Trade and other receivables are financial assets held for collecting the contractual cash flows of the asset, where the cash flows are solely payments of principal and interest that are not provided at below-market interest rates. They are subsequently measured at amortised cost using the effective interest method adjusted for any loss allowance. Refer to accounting policies of financial assets in Note 4.1 Financial Instruments - Initial recognition and subsequent measurement.

SCIENCE AND INDUSTRY ENDOWMENT FUND

NOTES TO AND FORMING PART OF THE FINANCIAL REPORT

for the period ended 30 June 2024

3.1 Financial Instruments

	2024	2023
3.1A: Categories of financial instruments		
Financial assets		
Financial assets measured at amortised cost		
Cash and cash equivalents	119,500,327	118,457,950
Trade and other receivables	1,744,969	1,875,112
Total financial assets measured at amortised cost	121,245,296	120,333,062
Total financial assets	121,245,296	120,333,062
Financial Liabilities		
Financial liabilities measured at amortised cost		
Suppliers payable	-	-
Total financial liabilities measured at amortised cost	-	-
Total financial liabilities	-	-
	2024	2023
3.1B: Net gains or losses on financial assets		
Financial assets measured at amortised cost		
Bank interest	5,814,909	3,153,988
Net gain from financial assets at amortised cost	5,814,909	3,153,988

Accounting Policy

Financial Assets

The Fund classifies its financial assets under *AASB 9 Financial Instruments* as financial assets measured at amortised cost.

The classification depends on both the entity's business model for managing the financial assets and contractual cash flow characteristics at the time of initial recognition. Financial assets are recognised when the entity becomes a party to the contract and, as a consequence, has a legal right to receive or a legal obligation to pay cash and derecognised when the contractual rights to the cash flows from the financial asset expire or are transferred upon trade date.

Financial Assets at Amortised Cost

Financial assets included in this category need to meet two criteria:

1. the financial asset is held in order to collect the contractual cash flows; and
2. the cash flows are solely payments of principal and interest (SPPI) on the principal outstanding amount.

Amortised cost is determined using the effective interest method.

Effective Interest Method

Income is recognised on an effective interest rate basis for financial assets that are recognised at amortised cost.

Financial liabilities

Financial liabilities are classified as either financial liabilities 'at fair value through profit or loss' or other financial liabilities. Financial liabilities are recognised and derecognised upon 'trade date'.

Financial Liabilities at Amortised Cost

Financial liabilities, including borrowings, are initially measured at fair value, net of transaction costs. These liabilities are subsequently measured at amortised cost using the effective interest method, with interest expense recognised on an effective interest basis. Supplier and other payables are recognised at amortised cost. Liabilities are recognised to the extent that the goods or services have been received (and irrespective of having been invoiced).

SCIENCE AND INDUSTRY ENDOWMENT FUND

NOTES TO AND FORMING PART OF THE FINANCIAL REPORT

for the period ended 30 June 2024

4.1 Related Parties

Accounting Policy

The Fund is a wholly controlled subsidiary of CSIRO. The Trustee is the Chief Executive of CSIRO who is remunerated through CSIRO and not paid an additional salary for his role as Trustee of the Fund. There were no transactions during the reporting period between the Trustee and the Fund. Related parties to this entity other than the Trustee are other Australian Government entities.

In considering relationships with related entities and transactions entered into during the reporting period by the Fund, it has been determined that there are no related party transactions required to be separately disclosed when taking into account the details provided within other notes to these financial statements. Grant funds are administered and applied in accordance with Program Funding Agreements. Awarded grants are assessed against a set of established criteria prior to approval. All eligible applications are assessed equally.